Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Arthritis Rheumatol. 2014 Nov;66(11):3151–3159. doi: 10.1002/art.38788

Table 3.

ANCA and B-cell status at severe relapse and six months after re-treatment with RTX

Re-treatment with RTX
(initially randomized to RTX)		 First RTX course (initially
randomized to CYC/AZA)
N=15 N=11
ANCA at severe relapse
Rising 12 (80%) 8 (73%)
Positive 1 (7%) 1 (9%)
Negative 2 (13%) 2 (18%)
ANCA 6 months after re-treatment
Rising 1 (7%) 0 (0%)
Positive 5 (33%) 7 (64%)
Negative 9 (60%) 4 (36%)
B-cells at relapse leading to re-treatment
Depleted 1 (7%) 0 (0%)
Detectable 3 (20%) 5 (46%)
Reconstituted 11 (73%) 3 (27%)
Missing data 0 (0%) 3 (27%)
B-cells 6 months after re-treatment
Depleted 10 (67%) 8 (73%)
Detectable 1 (7%) 0 (0%)
Reconstituted 1 (7%) 2 (18%)
Missing data 3 (20%) 1 (9%)